looking at recent 4c reports that the business obviously has a...

looking at recent 4c reports that the business obviously has a product the market wants. The only issue seems to be with staff and manufacture costs it seems to cost about same amount to make as it sells for? I wonder if they are able to claim r and d refunds like many in the medical area.

If they can show consistent cash flow positive trading for a few quarters the share price should be well north of current levels. Hopefully they have good payment terms on the new shots so income generated appears in next 4c.